Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.
Extern länk för Alzinova AB
Pepparedsleden 1
Mölndal, Västra Götaland 43183, SE
Alzinova AB omdelade detta
Den sista dosen av vaccinkandidaten ALZ-101 har nu getts till samtliga patienter som deltar i högdosdelen av Alzinova ABs fas Ib-studie i Alzheimers sjukdom. – Med data från denna studiedel som väntas i början av 2025 är vi ett steg närmare att gå vidare till nästa fas av kliniska prövningar, vilket för oss närmare en behandling av denna förödande sjukdom, säger vd Tord Labuda. #lifescience #Alzheimers
Alzinova AB is pleased to announce that all patients in the high-dose cohort of our phase 1b study for the Alzheimer's vaccine candidate, ALZ-101, have received their final dose. This marks a critical milestone as we continue to explore the potential of our targeted, disease-modifying treatment for Alzheimer’s disease. With follow-up data from this part of the study expected in early 2025, we are moving closer to advancing to phase 2 and bringing hope to those impacted by this devastating disease. #Alzheimer #ClinicalTrials #HealthcareInnovation #Biopharma #ALZ101
Our new CEO, Tord Labuda, recently sat down with Redeye analyst Kevin Sule for an insightful "get to know" interview. Tord shares his experience, what he will focus on, his vision for Alzinova AB, and what he’s most looking forward to in the coming year. The full interview is now available on our website – don’t miss it! 👉 https://lnkd.in/dAFidkpG #Alzinova #Leadership #AlzheimersResearch #Biotech #Interview #Redeye
On October 23, the new CEO Tord Labuda of Alzinova AB will take the stage and present Alzinova at Redeye ABs event – Redeye Neurology Day. What: Redeye Neurology Day When: October 23th Time: 11.20 Where: Live stream at Redeyes website Link to the event in the comment section, put it in your calendar! #alzheimersresearch #presentation #investorevent
Meet our new CEO, Tord Labuda! In a recent interview with BioStock - Connecting Innovation and Capital, Tord shares insights into his extensive background in the pharmaceutical industry, his vision for Alzinova AB, and the exciting path ahead. With the phase Ib clinical trial of our Alzheimer’s vaccine ALZ-101 on track for completion in early 2025, and preparations for phase II, Tord discusses the opportunities that lie ahead for both Alzinova and the industry. Read the interview below! #Alzinova #Interview #lifescience
Med lång erfarenhet från ledande positioner inom läkemedelsbranschen har Tord Labuda tillträtt som ny vd för Alzinova AB. Bolaget befinner sig i en spännande utvecklingsfas, där den kliniska fas Ib-studien av Alzheimervaccinet ALZ-101 förväntas vara klar i början av 2025. Redan nu utforskar man möjligheter till licensavtal med ett större läkemedelsbolag inför fas II. #lifescience #Alzheimers
💡Do you know the risk factors associated with #Alzheimer's disease? 💡 The theme for this year’s #WorldAlzheimermonth is “Time to act on dementia, Time to act on Alzheimer’s” which aims to shed light to the fact that so many people still wrongly believe that dementia is a part of normal ageing. With an increasing number of people becoming more aware of Alzheimer's disease and its symptoms, it is also important to address the risk factors and what can be done to reduce the risks of developing the disease. Do you know what the main risk factors are? These are the top five to consider: - Physical inactivity - Smoking - Infrequent social contact - Depression - Air pollution By educating others about dementia and Alzheimer's disease while contributing to research as much as we can, Alzinova AB is continuing its efforts to develop its vaccine candidate ALZ-101 and antibody ALZ-201. #AlzheimerDisease #AlzheimerAwarenessMonth
Alzinova AB attends BIO-Europe! We are thrilled participate at BIO-Europe, that is being held in Sweden and our capital Stockholm in November this year! The event brings together thousands of international pharmaceutical industry experts, to encourage discussions on licensing deals and research collaborations among pharmaceutical companies. Our Business Development Director, Sebastian Hansson, will be there to promote the Company’s two exciting projects; our vaccine candidate ALZ-101 and antibody ALZ-201 against Alzheimer's disease. To explore collaboration and partnership opportunities, send a meeting request through the partnering platform or contact our team via email at info@alzinova.com or send Sebastian a DM here on LinkedIn. We look forward to showcasing our progress at BIO-Europe and exploring the possibilities for Alzinova! #BIOEurope #precisionmedicine #innovation #alzheimerresearch #partnering
Alzinova AB appoints Dr. Tord Labuda as new CEO! Alzinova is pleased to announce the appointment of Dr. Tord Labuda as CEO, starting October 1, 2024. Dr. Labuda brings more than 15 years of experience in senior positions in the pharmaceutical industry, covering therapeutic areas with a strong focus on inflammation and immunology. His expertise, from early-stage research through regulatory approvals to product launches, will be invaluable as Alzinova advances its work on developing treatments for Alzheimer's disease. We would also like to take this opportunity to express our appreciation for Carol Routledge's leadership while serving as acting CEO during this transition. We now look forward to continued progress under Dr. Labuda's leadership. To read the full press release, see the link in the comments. #AlzheimerResearch #Biotech #AlzheimersDisease #Healthcare
This week, Alzinova AB shared a big milestone! The first participant has successfully completed the entire phase 1b study with ALZ-101. This marks a significant step forward in our mission to develop an effective and safe treatment for Alzheimer’s disease. ALZ-101 is a potential breakthrough in fighting one of the world's most challenging neurodegenerative diseases. A heartfelt thank you to our dedicated team, partners, and participants who have helped us reach this important milestone. We’re excited to continue progressing towards the future of Alzheimer's treatment. Read the full press release, link in comments. #Alzheimers #Biotech #Innovation #ClinicalTrials #Healthcare
📣 September is Alzheimer's Awareness Month! 📣 As we are now in September, it's time to highlight World Alzheimer’s Month, let's take a moment to reflect on the impact of Alzheimer's disease and dementia on individuals, families, and communities. Alzheimer's Awareness Month is a crucial time to raise awareness, support those affected, and advocate for research and understanding of this challenging condition. #Alzheimer's disease is the most common cause of dementia, affecting millions of people worldwide. It not only robs individuals of their memories and cognitive abilities but also has far-reaching effects on their loved ones. This month serves as a reminder that we must stand together to support those facing this disease and work towards a world without Alzheimer's. 💫How you can get involved: 1️. Educate Yourself: Take time to learn about Alzheimer's disease, its symptoms, risk factors, and available resources. 2️. Support Caregivers: Caregivers play a crucial role in the lives of those with Alzheimer's. Offer your support, lend a listening ear, and provide respite when possible. 3. Share Your Story: If you or a loved one has been impacted by Alzheimer's, sharing your experience can raise awareness and reduce the stigma surrounding the disease. 4. Advocate for Change: Advocate for increased funding for Alzheimer's research and support services. Your voice can make a difference. 5. Follow Alzinova AB to learn more about our journey and our mission to make it possible for Alzheimer's patients to live an independent and active life. Let's work together to create a world where Alzheimer's disease is better understood, effectively treated, and ultimately prevented. #WorldAlzheimersMonth #AlzheimersResearch #AlzheimersDisease
Senaste finansieringsrunda
Anslag52 680,00 US$